DAVID Y. IGE
GOVERNOR OF HAWAII

BRUCE S. ANDERSON, Ph.D.
DIRECTOR OF HEALTH

STATE OF HAWAII
DEPARTMENT OF HEALTH
P. O. Box 3378
Honolulu, HI 96801-3378
doh.testimony@doh.hawaii.gov

Testimony in SUPPORT of SB0541 SD1 HD1
RELATING TO MEDICAL CANNABIS PRODUCTS.

REPRESENTATIVE ROY M. TAKUMI, CHAIR
HOUSE COMMITTEE ON CONSUMER PROTECTION & COMMERCE

Hearing Date: Thursday, March 28, 2019 Room Number: 329

Fiscal Implications: None identified.

Department Testimony: The Department of Health (DOH) SUPPORTS SB541 SD1 HD1 that:

1. Amends section 329D-1, HRS, to simplify the definition of manufactured cannabis product to "any product that has been manufactured using cannabis pursuant to section 329D-10, HRS;" and
2. Amends section 329D-10(a)(7) to change "transdermal patches" to "transdermal devices as approved by the department" to align with the intent of the Act 230, SLH 2016, Medical Cannabis Legislative Oversight Working Group.

DOH appreciates the amended language to allow the department to approve transdermal devices manufactured by licensees to ensure that they are appropriate and safe for use by patient. Certain types of transdermal devices may be potentially invasive and not appropriate for patient use of medical cannabis (e.g., microneedles or ablation to enhance skin permeability).

Thank you for the opportunity to testify.